Core Viewpoint - Senti Biosciences, Inc. has initiated a pilot clinical trial for SN301A, a CAR-NK cell therapy targeting hepatocellular carcinoma (HCC), in collaboration with Celest Therapeutics in China, marking a significant step in their strategic partnership and addressing a major health threat in the region [1][3][4]. Group 1: Clinical Trial Details - The trial aims to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of SN301A in patients with advanced GPC3-expressing HCC across multiple dose cohorts [2][4]. - The study will assess safety through adverse events and dose-limiting toxicities, alongside efficacy analyses using standard response criteria for liver cancer [2]. - SN301A will be administered in three dose levels during a 28-day treatment cycle, with patients potentially receiving multiple cycles based on their safety and efficacy results [4]. Group 2: Product and Technology Overview - SN301A is derived from the SENTI-301A Gene Circuit, designed to target the GPC3 antigen, which is expressed in 70% to 90% of HCC cases, while having low or no expression in normal adult tissues [5]. - The therapy incorporates calibrated release interleukin-15 (crIL-15) to stimulate immune cells and promote CAR-NK cell expansion and tumor killing [5]. - Preclinical data has shown robust in vitro and in vivo efficacy of SENTI-301A against relevant tumor cells [5]. Group 3: Market Context and Strategic Importance - Liver cancer is the second leading cause of cancer-related death in Asia, with over 40% of global HCC cases reported in China, highlighting the significant unmet medical need that SN301A aims to address [3][4]. - Senti Bio retains all development and commercialization rights for SENTI-301A outside of mainland China, Hong Kong, Macau, and Taiwan, indicating a strategic focus on the Chinese market [3].

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] - The company aims to create therapies that precisely target cancer cells while sparing healthy cells, enhancing specificity, and controlling drug expression post-administration [3] - Senti Bio's pipeline includes off-the-shelf CAR-NK cells equipped with Gene Circuits for targeting difficult liquid and solid tumors, and it has shown preclinical success in T cells and other modalities [3] Recent Developments - On November 26, 2024, Senti Bio's Compensation Committee granted stock options to three new employees, totaling 49,778 shares at an exercise price of $2.11 per share [1] - These stock options were awarded as an inducement for the employees to join the company, in compliance with NASDAQ Listing Rule 5635(c)(4) [2] - The stock options were granted under the Company's 2022 Inducement Equity Plan, which was adopted on August 5, 2022 [2]

Core Insights - Senti Biosciences, Inc. announced positive initial data from a phase I study for its CAR-NK cell therapy candidate, SENTI-202, targeting relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [1][4][7] Company Performance - Following the announcement, Senti Biosciences' shares surged by 363% on December 2 [2] - Year-to-date, SNTI stock has increased by 51.5%, contrasting with a 7.1% decline in the industry [3] Clinical Study Results - In the phase I study, two out of three AML patients treated at the lowest dose level (1.0 billion CAR+ NK cells) achieved complete remission, confirmed by bone marrow biopsy [4] - Both patients also achieved measurable residual disease (MRD) negative status, indicating no detectable cancer cells [5] - Treatment with SENTI-202 was generally well-tolerated among all three AML patients [6] Future Developments - The FDA cleared Senti Biosciences' IND application for SENTI-202 in December 2022, allowing clinical studies to commence [7] - The phase I study is expected to enroll around 20 patients, with a higher dose cohort currently enrolling [8] - Additional safety and efficacy data, including durability data, is anticipated in 2025 [9] Pipeline Expansion - Senti Biosciences has another candidate, SENTI-301A, and has entered a collaboration with Celest Therapeutics for its clinical development in China [10]

Senti Biosciences, Inc. SNTI stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro.The company reported initial clinical data from a Phase 1 trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for relapsed/refractory hematologic malignancies including acute myeloid leukemia.SENTI-202 is designed to selectiv ...

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2024 and provided a summary of recent pipeline and corporate highlights. “Over the past quarter, we have continued to execute on our clinical milestones and look forward to sharing initial results fro ...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CARNK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C. Wainwright's 26th Annual Global Investment Conference Format: Prese ...

Financial Performance - Senti Bio reported a net loss of $11.2 million for Q2 2024, compared to $18.7 million in the same period in 2023[4][10] - Cash and cash equivalents stood at $15.9 million as of June 30, 2024, down from $35.9 million at the end of 2023[4][9] - Total assets decreased to $86.9 million as of June 30, 2024, from $119.5 million at the end of 2023[9] Research and Development (R&D) - R&D expenses increased to $9.2 million in Q2 2024, up from $6.9 million in Q2 2023, primarily due to manufacturing costs for wholly-owned programs[4][10] - Senti Bio received an $8 million grant from CIRM to support the clinical development of SENTI-202 for relapsed/refractory hematologic malignancies[2] - Patient dosing has commenced in the Phase 1 clinical trial of SENTI-202 for AML, with initial efficacy data expected by year-end 2024[3] - Senti Bio plans to initiate a pilot trial of SENTI-301A for hepatocellular carcinoma in China through a partnership with Celest, with first patient dosing expected in Q4 2024[3] General and Administrative (G&A) Expenses - G&A expenses decreased to $4.2 million in Q2 2024, down from $9.2 million in Q2 2023, mainly due to a reduction in headcount[4][10] Corporate Actions - The company effected a 1-for-10 reverse stock split in July 2024 to comply with Nasdaq's minimum bid price requirement[3] Receivables and Transactions - Senti Bio anticipates $18.9 million in receivables from the GeneFab transaction upon satisfaction of certain conditions[4]

Core Insights - Senti Biosciences, Inc. is advancing its clinical trials for SENTI-202, targeting relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [1][4] - The company has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of SENTI-202 [3] - Senti Bio is also preparing to initiate a pilot trial for SENTI-301A in hepatocellular carcinoma (HCC) in China through a partnership with Celest Therapeutics [2][5] Corporate and Pipeline Highlights - The Phase 1 clinical trial for SENTI-202 has commenced, focusing on patients with relapsed/refractory AML in the U.S. and Australia, with initial efficacy data expected by the end of 2024 [4] - The company is developing SENTI-301A for solid tumors in China, with the first patient expected to be dosed in Q4 2024 [5] - A reverse stock split of 1-for-10 was executed in July 2024 to comply with Nasdaq's minimum bid price requirement [6] Financial Results - As of June 30, 2024, Senti Bio reported cash and cash equivalents of $15.9 million, with additional receivables of $18.9 million anticipated from the GeneFab transaction [7] - Research and development expenses increased to $9.2 million for Q2 2024, up from $6.9 million in Q2 2023, primarily due to manufacturing costs [7] - General and administrative expenses decreased to $4.2 million in Q2 2024 from $9.2 million in Q2 2023, attributed to a reduction in headcount [7] Upcoming Events - Senti Bio plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, and Chardan's 8th Annual Genetic Medicines Conference from September 30 to October 1, 2024 [8]

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines ("CIRM"). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant wil ...

Core Insights - Senti Biosciences, Inc. has received an $8 million grant from the California Institute for Regenerative Medicines to support the clinical development of its investigational cell therapy SENTI-202 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia [1][2] Company Overview - Senti Bio is a biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, aiming to create therapies with enhanced precision and control [6] - The company is advancing its pipeline with off-the-shelf CAR-NK cells designed to target challenging liquid and solid tumor indications [6] Product Development - SENTI-202 is a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow cells [3] - The therapy includes three main components: an OR GATE for activating CAR targeting, a NOT GATE for protecting healthy cells, and calibrated-release IL-15 technology to enhance cell persistence and activity [3] - A Phase 1 clinical trial for SENTI-202 is currently enrolling adult patients with relapsed/refractory CD33 and/or FLT3 expressing hematologic malignancies, with initial efficacy data expected by the end of 2024 [2][3] Market Context - Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, with an estimated 20,800 new cases in the U.S. in 2024 and a five-year survival rate of approximately 30% [5] - Current treatment options for relapsed or refractory AML are limited, with median overall survival typically less than seven months [5]